Particle.news
Download on the App Store
7 ARTICLES
·
1h ago

Carmat Wins Reprieve as Versailles Court Delays Liquidation Decision to Nov. 25

A fresh call for takeover bids creates a final window for potential buyers following the collapse of the only rescue plan.

« Très vite, un obstacle majeur apparaît : la taille. Trop volumineuse, la prothèse Carmat ne convient pas à une large partie des patients – notamment les femmes. Seules trois ont pu en bénéficier. »
Au siège de l'entreprise Carmat qui fabrique des coeurs artificiels, à Bois-d'Arcy dans les Yvelines, le 29 août 2018
Au siège de l'entreprise Carmat qui fabrique des coeurs artificiels, à Bois-d'Arcy dans les Yvelines, le 29 août 2018
Image

Overview

  • The company remains at risk of being wound up, which its management still describes as extremely probable.
  • Board chairman Pierre Bastid says he will file a new takeover proposal with other investors after his initial €150 million bid was declared void in September.
  • The court’s deferral provides roughly six weeks for concrete offers to be submitted under the renewed process.
  • Aeson has been implanted in 122 patients; 19 people remain supported by the device, and Carmat says their follow-up care is a priority even in case of liquidation.
  • After about €550 million invested, a unit price near €200,000 and a narrow eligible patient pool undermined the business model, and trading in the shares is suspended.